New ESC-EAPCI consensus statement recommends renal denervation*

Download the summary

The European Society of Cardiology (ESC) Council on Hypertension and European Association of Percutaneous Cardiovascular Interventions (EAPCI) recommend renal denervation as complementary treatment strategy, adjunctive to lifestyle and pharmacological interventions, for uncontrolled hypertension patients.*

Consensus key take-aways

Clinical evidence review

1. Several high-quality studies, including randomised, sham-controlled confirmed both the blood pressure (BP)-lowering efficacy and safety of renal denervation in a broad range of patients with hypertension.

2. Data from registries and sham-controlled trials indicate a sustained BP-lowering effect of RDN for up to three years.

Patient selection criteria

1. Renal denervation may be used in adult patients with uncontrolled resistant hypertension:

• office BP≥140/≥90 mmHg
• confirmed by 24-hour ambulatory systolic BP ≥130 mmHg or daytime systolic BP ≥135mmHg
• treated with ≥3 antihypertensive drugs
• eGFR ≥40 ml/min/1.73 m²

2. Renal denervation may be a possible treatment option in patients:

• unable to tolerate antihypertensive drugs in the long term
• express a preference to undergo RDN in a tailored, shared decision-making process.

3. The decision-making process should take into account:

• The patient’s global cardiovascular (CV) risk and/or
• The presence of hypertension-mediated organ damage or
• CV complications.

High CV risk favours the use of RDN.

ESC - EAPCI clinical consensus statement

Access the publication of the ESC - EAPCI clinical consensus statement published on EHJ and EuroIntervention on February 15^th.

Read the paper on EHJ

Read the paper on EI

Renal denervation
The third pillar for hypertension management*

Lifestyle
modifications

Medications

Renal
denervation

Learn what experts think about the new ESC-EAPCI consensus statement

Watch Prof. Felix Mahfoud present the key takeaway from the ESC-EAPCI clinical consensus statement and why RDN can be considered a third pillar in the treatment of hypertension.

Watch Prof. Atul Pathak present the key takeaway from the ESC-EAPCI clinical consensus statement and how the document can help on patient selection.

Additional resources

Learn more about renal denervation

Explore the extensive evidence supporting RDN, discover the Symplicity Spyral^TM system and learn which patient could benefit.

Explore the system

Listen to the experts

Find links to third party education sites and view recordedsessions from global RDN experts.

Access the videos

Download one-pager

Let's get in touch!

We are here to support you. In case you have questions or simply want to receive news and updates on renal denervation, please complete the form below.

*Indicates Required Field

Please select at least one option below:*

I would like to be contacted by a Medtronic representative

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

References

Barbato E, Mahfoud F, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. Published online Feb. 15, 2023.

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved.